Artwork

Content provided by Bleav + Dave Knapp Man On The Mounjaro and Dave Knapp Man On The Mounjaro. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bleav + Dave Knapp Man On The Mounjaro and Dave Knapp Man On The Mounjaro or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25

23:05
 
Share
 

Manage episode 467312213 series 3550124
Content provided by Bleav + Dave Knapp Man On The Mounjaro and Dave Knapp Man On The Mounjaro. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bleav + Dave Knapp Man On The Mounjaro and Dave Knapp Man On The Mounjaro or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

πŸ“š Book Relaunch: The book β€œDecoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.
⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.
πŸ”¬ Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.
πŸ’Š PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.
πŸ“ˆ Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.
πŸ₯ Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.
πŸŽ‰ Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions

  continue reading

119 episodes

Artwork
iconShare
 
Manage episode 467312213 series 3550124
Content provided by Bleav + Dave Knapp Man On The Mounjaro and Dave Knapp Man On The Mounjaro. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bleav + Dave Knapp Man On The Mounjaro and Dave Knapp Man On The Mounjaro or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

πŸ“š Book Relaunch: The book β€œDecoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.
⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.
πŸ”¬ Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.
πŸ’Š PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.
πŸ“ˆ Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.
πŸ₯ Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.
πŸŽ‰ Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions

  continue reading

119 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play